Navigation Links
MAQUET Cardiovascular Completes Acquisition of Atrium Medical Corporation
Date:11/7/2011

. Both acquisitions are part of the MAQUET Cardiovascular organization today and product revenues from those acquisitions and continued organic growth continue to play a significant role in MAQUET Cardiovascular's dramatic revenue growth.

About Atrium

Atrium's vast expertise in medical device technologies for the treatment of coronary and vascular disease, chest trauma, hernia and soft tissue injury has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and general surgery. Maintaining a commitment to the latest ISO13485 Quality Standards, state-of-the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in those healthcare segments that require more advanced surgical intervention for improvements in patient outcomes. For more information please visit www.atriummed.com.

About MAQUET

As a trusted partner for hospitals and clinicians since 1838, MAQUET is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. MAQUET develops and designs innovative products and therapeutic applications for the operating room, hybrid OR/cath lab, intensive care unit and patient transport within acute care hospitals, improving outcomes and quality of life for patients.

Cardiovascular specialties include intra-aortic balloon counterpulsation (IABC) therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation. The Critical Care portfolio includes market-leading intensive care ventilators and anesthesia machines. MAQUET also equips Surgical Workplaces with critical infrastructure, such as flexible room design for OR and ICU; OR tables; lights and ceiling supply uni
'/>"/>

SOURCE MAQUET Cardiovascular
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps
2. MAQUET Cardiovascular Receives FDA 510(k) Clearance and CE Mark for Its New SENSATION PLUS™ Intra-Aortic Balloon Catheter
3. UPDATE - MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
4. MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
5. MAQUET Cardiovascular Launches New VASOVIEW 6 PRO Endoscopic Vessel Harvesting System
6. MAQUET Cardiovascular Launches Advanced VASOVIEW Technology for Endoscopic Vessel Harvesting Procedures in Cardiac Surgery
7. MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients
8. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
9. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
10. Beating Cardiovascular Disease: Continuing Medical Education Course (CME) in Jackson, MS
11. DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... WELWYN GARDEN CITY, England and ... Heptares Therapeutics, the leading GPCR drug discovery and development company, ... Akira Usui as a Consultant to augment the Company,s ... Asian territories. Mr Usui has more than 15 years ... pharmaceutical industry including senior roles at Perlegen Sciences, Inc., Roche Pharma ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... 23, 2013  A recently published clinical study conducted ... Texas , demonstrates that 3D mammography (breast tomosynthesis) ... The study, "Implementation of Breast Tomosynthesis ... led by Stephen L. Rose , ... American Journal of Roentgenology (AJR). The AJR ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
... April 7, 2011 Inhibitex, Inc. (Nasdaq: INHX ... of 11,463,415 shares of its common stock, at a purchase ... of $47 million. The net proceeds to Inhibitex from the sale ... offering expenses, are expected to be approximately $44 million.  Inhibitex ...
Cached Medicine Technology:Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3
(Date:5/25/2013)... Acuity Games ’ innovative brain games have ... Word Hunt is available today, expanding it beyond its ... 2, Sudoku and Matchematics will roll out over the next ... lifetime brain fitness measurement have been re-optimized for the iPhone's ... brain fitness measurement in your pocket. What could be ...
(Date:5/25/2013)... 2013 IBISWorld estimates that revenue for the ... annual rate of 28.7% to $1.0 billion in the five ... 2002 and 2008, no new cell therapy products were introduced, ... growth during that period. In the years since, however, the ... This factor contributed to the industry's fast growth during the ...
(Date:5/25/2013)... Houston, Texas (PRWEB) May 25, 2013 ... more stressful than finals week. Increasingly, they are ... them stay awake and study. For more on ... Associates, a drug treatment facility, warns that students ... through finals” are at risk for developing a ...
(Date:5/25/2013)... Ayurveda is the traditional medicine of India. Translated ... While a medical science, its scope enters into the realms ... philosophy is that disease is the end result of living ... order to re-establish optimal health, we must discover where we ... style which brings us back into harmony. , The California ...
(Date:5/25/2013)... The current residents of Back2Basics - Long Term ... staff all came together Saturday, May 18th to celebrate the ... Cuisine, the residents got up to thank Roy Duprez, CEO ... road to recovery, and giving them a second chance at ... 2010 after realizing the need for a long-term facility. ...
Breaking Medicine News(10 mins):Health News:Acuity Games Apps Come to the iPhone 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2
... Conn., March 30 Anthem Blue Cross and Blue ... a Brand Excellence Award from the Blue Cross and ... Blue Cross and Blue Shield companies that excel in ... Shield Brand image."The Blue Cross and Blue Shield Brands ...
... an important building block of social interaction that prompts ... these children pay attention to physical relationships between movement ... the Yale School of Medicine report their results in ... , "Human infants are born in a fragile ...
... March 30 Golub Capital today announced that it ... equity to support the acquisition of Network Express, Inc., ... Street Capital. The combination of Ace Expediters, Inc., (which ... Network Express, Inc., creates the leading dedicated route logistics ...
... newborn is small, doctors should be aware, study says , , ... their due date have an increased risk of developmental delays ... thought to have little to no risk of long-term problems, ... "late pre-term") have as much as a 36 percent higher ...
... with Uncertain Origins Demonstrates Unmatched PerformanceREDWOOD CITY, Calif., March ... focused on oncology, announced today that the Journal ... the results of the Pathwork(R) Tissue of Origin Test ... a 1,550-Gene Expression Profile for Identification of Tumor Tissue ...
... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, today reported operational and financial results for the ... December 31, 2008 and 2007, the Company reported revenues ... for the full year 2008 consisted primarily of contract ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in Connecticut Receives Prestigious Brand Excellence Award 2Health News:Yale researchers discover mechanism for 2Health News:Golub Capital Provides Debt Financing to Support the Acquisition of Network Express, Inc., by Ace Expediters, Inc. 2Health News:Babies Born Only 2 to 3 Weeks Early May Face Development Delays 2Health News:Babies Born Only 2 to 3 Weeks Early May Face Development Delays 3Health News:Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology 2Health News:Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology 3Health News:PharmAthene Reports Year End 2008 Financial Results 2Health News:PharmAthene Reports Year End 2008 Financial Results 3Health News:PharmAthene Reports Year End 2008 Financial Results 4Health News:PharmAthene Reports Year End 2008 Financial Results 5Health News:PharmAthene Reports Year End 2008 Financial Results 6Health News:PharmAthene Reports Year End 2008 Financial Results 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: